Companies similar to Chemilines Healthcare India for Executive Regulatory Affairs in Surat
![]()
Chemilines Healthcare India
Executive Regulatory Affairs Salary
2 - 5 years exp. (4 salaries) | ₹3 L/yr - ₹3.4 L/yr |
Company name | Avg Annual Salary | Open Jobs |
---|---|---|
Fides RAA Executive Regulatory Affairs Salary
0 - 4 years exp. (4 salaries) | ₹1.8 L/yr - ₹2.2 L/yr | |
![]() Globela Pharma Executive Regulatory Affairs Salary
1 - 5 years exp. (4 salaries) | ₹2.4 L/yr - ₹2.7 L/yr | |
Login to view exact salary
| ||
![]() Trident Lifeline Executive Regulatory Affairs Salary
1 - 7 years exp. (4 salaries) | ₹2 L/yr - ₹6.5 L/yr | |
Experience wise Chemilines Healthcare India Executive Regulatory Affairs salaries in Surat
Last Updated: 22 Nov 2023
Experience | Avg Annual Salary |
---|---|
2 years (AmbitionBox Estimate) |
₹3
L/yr
- ₹5.9
L/yr
|
3 years (AmbitionBox Estimate) |
₹3
L/yr
- ₹5.9
L/yr
|
Login to view exact salary
| |
4 years (AmbitionBox Estimate) |
₹3
L/yr
- ₹5.8
L/yr
|
5 years (AmbitionBox Estimate) |
₹3
L/yr
- ₹5.7
L/yr
|
Salary related reviews for Chemilines Healthcare India
Discover interview dos and don'ts from real experiences
Top trending discussions







Chemilines Healthcare India Executive Regulatory Affairs Salary FAQs
- Trident Lifeline Executive Regulatory Affairs Salary - ₹2.0 Lakhs to ₹6.5 Lakhs per year
- Globela Pharma Executive Regulatory Affairs Salary - ₹2.4 Lakhs to ₹2.7 Lakhs per year
- Fides RAA Executive Regulatory Affairs Salary - ₹1.8 Lakhs to ₹2.2 Lakhs per year
Tell us how to improve this page.
- Home >
- Salaries >
- Chemilines Healthcare India Salaries >
- Chemilines Healthcare India Executive Regulatory Affairs Salaries >
- Chemilines Healthcare India Executive Regulatory Affairs Salaries in Surat
Chemilines Healthcare India Executive Regulatory Affairs salary
in
Surat
ranges between ₹3
Lakhs to ₹3.4
Lakhs with an average annual salary of
₹. Salary estimates are based on
4
Chemilines Healthcare India latest salaries received from various employees of
Chemilines Healthcare India.